Seronegative antibody‐mediated neurology after immune checkpoint inhibitors
Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune‐related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody‐mediated neurological diseases after checkpoint inhibitors:...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Wiley
2018
|
| _version_ | 1797055032807391232 |
|---|---|
| author | Wilson, R Menassa, D Davies, A Michael, S Hester, J Kuker, W Collins, G Cossins, J Beeson, D Steven, N Maddison, P Rinaldi, S Jacob, S Irani, S |
| author_facet | Wilson, R Menassa, D Davies, A Michael, S Hester, J Kuker, W Collins, G Cossins, J Beeson, D Steven, N Maddison, P Rinaldi, S Jacob, S Irani, S |
| author_sort | Wilson, R |
| collection | OXFORD |
| description | Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune‐related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody‐mediated neurological diseases after checkpoint inhibitors: longitudinally extensive transverse myelitis, Guillain–Barré syndrome, and myasthenia gravis. All patients shared three characteristics: symptoms commenced 4 weeks after drug administration, responses to conventional immunotherapies were excellent, and autoantibodies traditionally associated with their syndrome were absent. However, serum immunoglobulins from the myelitis and Guillain–Barré syndrome patients showed novel patterns of tissue reactivity. Vigilance is required for antibody‐mediated neurology after checkpoint inhibitor administration. This phenomenon may inform the immunobiology of antibody‐mediated diseases. |
| first_indexed | 2024-03-06T19:05:45Z |
| format | Journal article |
| id | oxford-uuid:15100985-cf4d-4ef0-8a92-13b92df8ef69 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T19:05:45Z |
| publishDate | 2018 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:15100985-cf4d-4ef0-8a92-13b92df8ef692022-03-26T10:23:24ZSeronegative antibody‐mediated neurology after immune checkpoint inhibitorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:15100985-cf4d-4ef0-8a92-13b92df8ef69Symplectic Elements at OxfordWiley2018Wilson, RMenassa, DDavies, AMichael, SHester, JKuker, WCollins, GCossins, JBeeson, DSteven, NMaddison, PRinaldi, SJacob, SIrani, SCheckpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune‐related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody‐mediated neurological diseases after checkpoint inhibitors: longitudinally extensive transverse myelitis, Guillain–Barré syndrome, and myasthenia gravis. All patients shared three characteristics: symptoms commenced 4 weeks after drug administration, responses to conventional immunotherapies were excellent, and autoantibodies traditionally associated with their syndrome were absent. However, serum immunoglobulins from the myelitis and Guillain–Barré syndrome patients showed novel patterns of tissue reactivity. Vigilance is required for antibody‐mediated neurology after checkpoint inhibitor administration. This phenomenon may inform the immunobiology of antibody‐mediated diseases. |
| spellingShingle | Wilson, R Menassa, D Davies, A Michael, S Hester, J Kuker, W Collins, G Cossins, J Beeson, D Steven, N Maddison, P Rinaldi, S Jacob, S Irani, S Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title | Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title_full | Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title_fullStr | Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title_full_unstemmed | Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title_short | Seronegative antibody‐mediated neurology after immune checkpoint inhibitors |
| title_sort | seronegative antibody mediated neurology after immune checkpoint inhibitors |
| work_keys_str_mv | AT wilsonr seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT menassad seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT daviesa seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT michaels seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT hesterj seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT kukerw seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT collinsg seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT cossinsj seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT beesond seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT stevenn seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT maddisonp seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT rinaldis seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT jacobs seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors AT iranis seronegativeantibodymediatedneurologyafterimmunecheckpointinhibitors |